Pablo García Jaén: rFVIIa Shows Promise for Secondary Prophylaxis in Glanzmann Thrombasthenia
Pablo García Jaén, Specialist in Hematology and Hemotherapy at Salamanca University Healthcare Complex (CAUSA), shared on LinkedIn about a recent article he and his colleagues co-authored, published in RPTH, adding:
”Very pleased to share our recently published Brief Report in Research and Practice in Thrombosis and Haemostasis:
‘Efficacy and safety of recombinant activated factor VII for secondary prophylaxis in patients with Glanzmann thrombasthenia’
In this multicenter Spanish study, we describe the use of rFVIIa as secondary prophylaxis in patients with Glanzmann thrombasthenia and recurrent severe bleeding despite standard therapy.
We are proud to contribute to the limited evidence in this rare inherited platelet disorder and to share the first Spanish Brief Report focused on this field.
Many thanks to all participating centers, colleagues, patients and families, as well as GEAPC, RETPLAC and SETH, for making this collaborative work possible.”
Title: Efficacy and safety of recombinant activated factor VII for secondary prophylaxis in patients with Glanzmann thrombasthenia
Authors: Pablo García-Jaén, Nuria Fernández-Mosteirin, María Luisa Serrano, Susana Riesco, Carlos Aguilar, David Gabaldon, Sara Kanaan-Leis, Almudena González-Prieto, Raquel Portugal, María Carmen Mendoza, Carmen Gilabert, Ana Hortal, Lorena Díaz-Ajenjo, Ana Lama-Villanueva, Alba Mei González-Galán, Ana Sánchez-Fuentes, Rocío Benito, José Rivera, José Ramón González-Porras, José María Bastida
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 16, 2026, 13:53Honey Blankenship: United by a Shared Commitment to the Bleeding Disorders Community
-
Aug 16, 2026, 13:46Sagar Bejalwar: A Rare Bleeding Disorder and the Importance of Specialized Care
-
Aug 16, 2026, 13:39Sharun Khan: Advancing Regenerative Medicine Through Veterinary Translational Science
-
Aug 16, 2026, 13:21Francois Roubille: New ESC Consensus on Inflammation in Coronary Syndromes
-
Aug 16, 2026, 13:05Neil Morgan: Submit Your Abstract for BSHT 2027
-
Aug 16, 2026, 12:50Heba Youssef: Can Cefoperazone Cause Coagulopathy?
-
Aug 16, 2026, 12:35Mohammad Alkhalil: Stroke Remains a Dreaded Complication in TAVI
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?